Astrazeneca: ‘We’re too big to base our CEO’s pay on FTSE 100 peers’ February 18, 2025 Astrazeneca is too big and complex to base its chief executive’s pay packet on the rest of the FTSE index, according to the chair of its remuneration committee. Writing in the pharmaceutical giant’s annual report, chair Sheri McCoy said “UK-listed FTSE companies are not the right peer group for us to use” given the group’s [...]
Astrazeneca revenue surges amid Chinese import tax allegations February 6, 2025 Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical giant recorded $54bn (£43.3bn) in revenue for the year, a jump of 21 per cent on 2023’s levels. In its full-year results, the largest FTSE 100 firm revealed that revenue in Europe had skyrocketed 37 per cent. [...]
Astrazeneca: FTSE 100 giant shrugs off China worries with profit upgrade November 12, 2024 Pharmaceuticals giant Astrazeneca has reported double-digit sales growth on higher demand and said it remains committed to China despite the detention of a high-ranking staff member there. The FTSE 100 firm told markets this morning that total revenue rose 19 per cent to $39.2bn (£30.6bn) in the first nine months of the year. The London-listed [...]
US approves Astrazeneca lung cancer drug Imfinzi for treatment August 16, 2024 Astrazeneca’s lung cancer drug Imfinzi has been approved for treatment in the US to be used both before and after surgery, just days after the company’s market value hit £200bn for the first time. Imfinzi, which is meant to treat early-stage non-small cell lung cancer alongside chemotherapy, is administered before and after surgery. The approval [...]
How Astrazeneca became the London Stock Exchange’s newest £200bn firm August 14, 2024 Astrazeneca has become the most recent UK-listed company to achieve a market valuation of £200bn, a landmark achievement for both the pharmaceutical giant and the London Stock Exchange, as investors have been won over by its ambition and success with cancer treatments. The company’s shares rose by 1.1 per cent on Tuesday, propelling its market [...]
Can the UK’s stock market produce another £200bn company? August 14, 2024 Seismic events or a shift in valuations are likely necessary for more UK stocks to be worth £200bn, analysts have told City A.M., after Astrazeneca became the first company in six years to pass the milestone.
Astrazeneca shares fall after FTSE giant’s forecast lift fails to inspire July 25, 2024 In the first half of 2024, Astrazeneca reported an 18 per cent year-on-year increase in total revenue, reaching $2.6bn (£2bn).
FTSE 100 companies BT, Vodafone and Astrazeneca to report earnings this week July 21, 2024 Key quarterly earning updates from FTSE 100 companies next week, include Vodafone, BT and Astrazeneca.
UK less ready for next pandemic than before Covid – Oxford vaccinologist July 3, 2024 The UK's state apparatus is less prepared to deal with a pandemic today than it was before Covid, one of the professors in charge of the Oxford Astrazeneca vaccine rollout has warned.
‘Nobel prize of engineering’ finalist Sunamp to raise Series B as it mulls public offering July 2, 2024 An innovative battery firm nominated for the "nobel prize of engineering" is set to raise a Series B funding round in a few months with a future IPO becoming an increasingly "realistic proposition", its boss has said.